Quincy C Moore 3rd
Overview
Explore the profile of Quincy C Moore 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Castro R, Kandhola G, Kim J, Moore 3rd Q, Thompson A
Mol Pharm
. 2023 Sep;
20(11):5532-5542.
PMID: 37774674
Drug delivery systems (DDS) have evolved in the last decades with the development of hydrogels and particles. However, challenges such as high systemic uptake, side effects, low bioavailability, and encapsulation...
2.
Thompson A, Hackett C, Grady T, Enyinnia S, Moore 3rd Q, Nave F
Polymers (Basel)
. 2020 Sep;
12(9).
PMID: 32867143
Developing technologies for the reduction of biofouling and enhancement of membrane functionality and durability are challenging but critical for the advancement of water purification processes. Silver (Ag) is often used...
3.
Sanders M, Taylor S, Tullos N, Norcross E, Moore 3rd Q, Thompson H, et al.
BMC Ophthalmol
. 2013 Mar;
13:8.
PMID: 23496928
Background: Capsule and pneumolysin (PLY) are two major virulence factors of Streptococcus pneumoniae. S. pneumoniae is one of the leading causes of bacterial endophthalmitis. The aim of this study is...
4.
Norcross E, Sanders M, Moore 3rd Q, Marquart M
J Bacteriol Parasitol
. 2012 Jan;
2(2):108.
PMID: 22229113
Streptococcus pneumoniae is an important cause of bacterial keratitis, an infectious disease of the cornea. This study aimed to determine the importance of pneumolysin (PLY), a pneumococcal virulence factor, in...
5.
Norcross E, Sanders M, Moore 3rd Q, Taylor S, Tullos N, Caston R, et al.
Invest Ophthalmol Vis Sci
. 2011 Nov;
52(12):9232-43.
PMID: 22039231
Purpose: The purpose of this study was to determine whether active immunization against pneumolysin (PLY), or polysaccharide capsule, protects against the corneal damage associated with Streptococcus pneumoniae keratitis. Methods: New...
6.
Sanders M, Norcross E, Robertson Z, Moore 3rd Q, Fratkin J, Marquart M
Invest Ophthalmol Vis Sci
. 2010 Nov;
52(2):865-72.
PMID: 21051708
Purpose: To determine whether Streptococcus pneumoniae capsule was necessary for pathogenesis of pneumococcal endophthalmitis. Methods: An isogenic capsule-deficient strain was created using homologous recombination. New Zealand White rabbits were injected...
7.
Sanders M, Norcross E, Moore 3rd Q, Fratkin J, Thompson H, Marquart M
J Ocul Pharmacol Ther
. 2010 Nov;
26(6):571-7.
PMID: 21034245
Purpose: To determine whether immunization with pneumolysin (PLY) protects against pneumococcal endophthalmitis. Methods: New Zealand white rabbits were immunized with a mutant form of PLY that retains only 1% of...
8.
Sanders M, Moore 3rd Q, Norcross E, Sanfilippo C, Hesje C, Shafiee A, et al.
Cornea
. 2010 Sep;
30(1):83-90.
PMID: 20847656
Purpose: Determine the effectiveness of topical besifloxacin, gatifloxacin, and moxifloxacin in treating keratitis caused by 2 strains of Pseudomonas aeruginosa with different quinolone susceptibility profiles. Methods: Minimal inhibitory concentrations (MICs)...
9.
Sanders M, Moore 3rd Q, Norcross E, Shafiee A, Marquart M
J Ocul Pharmacol Ther
. 2010 Mar;
26(2):193-8.
PMID: 20334537
Purpose: To determine the effectiveness of topically applied besifloxacin, gatifloxacin, and moxifloxacin for the early treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) keratitis. Methods: Ten hours post-MRSA infection, rabbit eyes...
10.
Sanders M, Norcross E, Moore 3rd Q, Shafiee A, Marquart M
Cornea
. 2009 Sep;
28(9):1055-60.
PMID: 19724203
Purpose: The purpose of this study was to determine the effectiveness of topically applied besifloxacin (0.6%), gatifloxacin (0.3%), and moxifloxacin (0.5%) for the late treatment of experimental methicillin-resistant Staphylococcus aureus...